Evidence map›Paper›PMID 39402020›Full record

ArticleBlood cancer journal2024

Clonal dynamics of aggressive systemic mastocytosis on avapritinib therapy.

Xiaomeng Huang, Anthony D Pomicter, Jonathan Ahmann, Yi Qiao, Opal S Chen, Tracy I George, Nataly Cruz-Rodriguez, Sameer Ahmad Guru, Gabor T Marth, Michael W Deininger

Abstract readCase ReportsLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xiaomeng HuangUtah Center for Genetic Discovery, University of Utah, Salt Lake, UT, USA.ORCID 0000-0001-9651-7503
Anthony D PomicterDivision of Hematology Biorepository, Huntsman Cancer Institute, University of Utah, Salt Lake, UT, USA.ORCID 0000-0002-3977-0841
Jonathan AhmannDivision of Hematology Biorepository, Huntsman Cancer Institute, University of Utah, Salt Lake, UT, USA.
Yi QiaoUtah Center for Genetic Discovery, University of Utah, Salt Lake, UT, USA.
Opal S ChenHigh-throughput Genomics, Huntsman Cancer Institute, University of Utah, Salt Lake, UT, USA.ORCID 0000-0001-6815-3642
Tracy I GeorgeDepartment of Pathology, School of Medicine, University of Utah, Salt Lake, UT, USA.ORCID 0000-0001-5478-7847
Nataly Cruz-RodriguezVersiti Blood Research Institute, Milwaukee, WI, USA.
Sameer Ahmad GuruVersiti Blood Research Institute, Milwaukee, WI, USA.
Gabor T Marth *Utah Center for Genetic Discovery, University of Utah, Salt Lake, UT, USA. gmarth@genetics.utah.edu.
Michael W Deininger *Versiti Blood Research Institute, Milwaukee, WI, USA. mdeininger@versiti.org.ORCID 0000-0002-2987-1331

Funding

UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI KATHARINE S ULLMAN · 1986 to 2026
$72.6M
Monitoring tumor subclonal heterogeneity over time and spaceU24CA209999 · NCI · UNIVERSITY OF UTAH · PI MARTH, GABOR T, QUINLAN, AARON R · 2016 to 2020
$3.9M
Targeting the Metabolic Regulator SIRT5 in Acute Myeloid LeukemiaR01CA254354 · NCI · VERSITI WISCONSIN, INC. · PI DEININGER, MICHAEL W. · 2020 to 2024
$2.9M
The function of MS4A3 in normal and malignant hematopoiesisR01CA268496 · NCI · VERSITI WISCONSIN, INC. · PI Michael W. Deininger · 2023 to 2026
$2.0M
Strategies to target BCR-ABL1 compound mutants in CML and Ph+ ALLR01CA257602 · NCI · VERSITI WISCONSIN, INC. · PI DEININGER, MICHAEL W. · 2021 to 2025
$1.8M
From genomics to natural language processing: A protected environment for research computing in the health scienceS10OD021644 · OD · UNIVERSITY OF UTAH · PI CHEATHAM, THOMAS E. · 2017 to 2017
$494k
NCI NIH HHS P30 CA042014NCI NIH HHS R01 CA254354NCI NIH HHS R01 CA257602NCI NIH HHS R01 CA268496NCI NIH HHS U24 CA209999NIH HHS S10 OD021644U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (National Cancer Institute Division of Cancer Epidemiology and Genetics) P30CA042014U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (National Cancer Institute Division of Cancer Epidemiology and Genetics) R01CA254354U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (National Cancer Institute Division of Cancer Epidemiology and Genetics) R01CA257602U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (National Cancer Institute Division of Cancer Epidemiology and Genetics) R01CA268496U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (National Cancer Institute Division of Cancer Epidemiology and Genetics) U24CA209999
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Mastocytosis, SystemicAvapritinibHumansProtein Kinase InhibitorsProto-Oncogene Proteins c-kitPyrazinesPyrazolesTriazinesAvapritinibProtein Kinase InhibitorsProto-Oncogene Proteins c-kitPyrazinesPyrazolesTriazines

Identifiers

PMID39402020
PMCPMC11473837

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.